| Source: |
Puerta , R , Cano , A , García-González , P , García-Gutiérrez , F , Capdevila , M , de Rojas , I , Olivé , C , Blázquez-Folch , J , Sotolongo-Grau , O , Miguel , A , Montrreal , L , Martino-Adami , P , Khan , A , Orellana , A , Sung , Y J , Frikke-Schmidt , R , Marchant , N , Lambert , J C , Rosende-Roca , M , Alegret , M , Fernández , M V , Marquié , M , Valero , S , Tárraga , L .... |
| Description: |
High-throughput proteomic platforms are crucial to identify novel Alzheimer’s disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan ® 7k) and antibody-based (Olink ® Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan ® assays analyzing the same samples, and between SomaScan ® and Olink ® results. Association analyses were performed between proteomic measures, CSF biological traits, sample demographics, and AD endophenotypes. Our 12-category metric of reproducibility combining correlation analyses identified 2428 highly reproducible SomaScan CSF measures, with over 600 proteins well reproduced on another proteomic platform. The association analyses among AD clinical phenotypes revealed that the significant associations mainly involved reproducible proteins. The validation of reproducibility in these novel proteomics platforms, measured using this scarce biomaterial, is essential for accurate analysis and proper interpretation of innovative results. This classification metric could enhance confidence in multiplexed proteomic platforms and improve the design of future panels. |